Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the most promising penny stocks under $5. On July 24, Rocket Pharmaceuticals announced a strategic corporate reorganization and pipeline prioritization to focus its resources on its adeno-associated virus/AAV cardiovascular platform and the regulatory submission for KRESLADI (formerly RP-L201) for severe leukocyte adhesion deficiency-I/LAD-I.
The company is implementing a workforce reduction of ~30%. This, along with other cost-saving measures, is expected to decrease Rocket’s 12-month operating expenses by ~25%. As a result, the company anticipates that its current cash resources will fund operations into Q2 2027.
Scientific equipment in a lab setting, revealing the cutting edge of biotechnology research.
This estimate does not account for any potential proceeds from a Priority Review Voucher, which may be granted upon the FDA approval of KRESLADI. As part of this realignment, the company anticipates delays in the Fanconi Anemia (FA; RP-L102) and Pyruvate Kinase Deficiency (PKD; RP-L301) programs, with FDA approval for RP-L102 no longer expected in 2026.
Rocket Pharmaceuticals Inc. operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
